Figma Shares Indicated To Open $105/$110
On Friday, B.Riley adjusted its outlook on Corbus Pharmaceuticals (NASDAQ:CRBP), reducing the price target to $40 from the previous $85 while maintaining a Buy rating. The revision followed the announcement of clinical trial results from a separate company, Novo Nordisk (NYSE:NVO), which reported outcomes that were below expectations and had a negative impact on Corbus Pharmaceuticals' shares.
Novo Nordisk disclosed top-line results from a Phase II study of INV-202 at 16 weeks, which showed modest efficacy and an increase in CNS-related adverse events. The findings led to a significant drop in Corbus Pharmaceuticals' market value, as investors perceived the results to have implications for Corbus' drug candidate CRB-913.
Despite the setback, B.Riley remains optimistic about Corbus' future prospects, particularly its nectin-4 targeting agent, CRB-701. The agent has demonstrated promising early data in the treatment of cervical cancer. This positive aspect contributes to the firm's continued endorsement of Corbus Pharmaceuticals with a Buy rating.
The lowered price target reflects a revised assessment of the likelihood of success for CRB-913, which has been impacted by the recent clinical trial results from Novo Nordisk. The adjustment takes into account the perceived risks and potential of Corbus' pipeline following the recent market developments.
B.Riley's decision to maintain a Buy rating indicates a belief in the underlying value and potential of Corbus Pharmaceuticals, despite the need to adjust expectations for one of its key drug candidates. The firm's stance is based on the broader portfolio and the early successes of other treatments being developed by Corbus.
In other recent news, Corbus Pharmaceuticals has been the focus of several analyst updates following mixed trial results. Despite disappointing data from the drug monlunabant, Oppenheimer maintains an Outperform rating for Corbus, highlighting the potential of the drug CRB-913 due to its lower central nervous system penetration. Mizuho Securities also retained its Outperform rating on Corbus, citing promising developments in the obesity treatment sector and potential success of CRBP-913.
Oppenheimer further increased its price target for the company from $80 to $88 following Corbus's second-quarter results, which revealed a strengthened financial position and promising updates on the clinical development timelines for CRB-913. B.Riley initiated coverage on Corbus with a Buy rating and a price target of $85.00, recognizing the potential of the company's developmental drug candidates, particularly CRB-913, a weight loss agent, and CRB-701, a drug showing promise in cervical cancer treatment.
InvestingPro Insights
As Corbus Pharmaceuticals navigates the aftermath of Novo Nordisk's clinical trial results, real-time data from InvestingPro offers a deeper financial perspective on the company. With a Market Cap of approximately $251.54 million and a Price to Book ratio of 4.96 as of Q2 2024, Corbus shows a significant valuation in the biopharmaceutical space. Despite not being profitable over the last twelve months, with an Operating Income of -$40.2 million, the company has demonstrated a strong return over the last three months, with a 21.16% Price Total Return, and an even more impressive 664.79% over the last year.
InvestingPro Tips suggest a mixed outlook. On one hand, Corbus holds more cash than debt, a positive indicator of financial health, and analysts have revised their earnings upwards for the upcoming period, signaling potential optimism in the company's future. On the other hand, the company suffers from weak gross profit margins and is not expected to be profitable this year. The stock's volatility is also a factor for investors to consider.
With these metrics in mind, B.Riley's revised price target and Buy rating may reflect not only the immediate impact of the clinical trial results but also the company's financial resilience and the potential for its other drug candidates. For those interested in a comprehensive analysis, InvestingPro offers additional insights, including over ten unique tips for Corbus Pharmaceuticals, available at https://www.investing.com/pro/CRBP.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.